TY - JOUR
T1 - Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults
AU - the Japan Society for Haematopoietic Cell Transplantation
AU - Arai, Yasuyuki
AU - Kondo, Tadakazu
AU - Shigematsu, Akio
AU - Tanaka, Junji
AU - Ohashi, Kazuteru
AU - Fukuda, Takahiro
AU - Kawakita, Toshiro
AU - Mori, Takehiko
AU - Hoshino, Takumi
AU - Onizuka, Makoto
AU - Ozawa, Yukiyasu
AU - Yoshida, Shuro
AU - Ueda, Yasunori
AU - Mizuno, Ishikazu
AU - Atsuta, Yoshiko
AU - Mizuta, Shuichi
N1 - Funding Information:
The authors would like to thank all the physicians and data managers at the centres who contributed valuable data on transplantation to the Japan Society for Haematopoietic Cell Transplantation (JSHCT). We also thank the members of the Data Management Committees of JSHCT. Funding: This study was supported by research funding from the Ministry of Education, Science, Sports, and Culture in Japan to T. Kondo.
Publisher Copyright:
© 2017 John Wiley & Sons Ltd
PY - 2017/7
Y1 - 2017/7
N2 - The efficacy of high-dose cytarabine (HDCA) plus cyclophosphamide/total-body irradiation (CY/TBI) has been proved in cord blood transplantation (CBT) for acute lymphoblastic leukaemia (ALL), but not in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT). In this cohort study, we compared the prognosis of CY/TBI (N = 1244) and HDCA/CY/TBI (N = 316) regimens in BMT/PBSCT for ALL. The addition of HDCA decreased post-transplant relapse, while significantly increasing non-relapse mortality (risk ratio, 1·33), and overall survival was not improved. The positive effects of HDCA reported in CBT cannot be extrapolated to BMT/PBSCT, and HDCA may not be recommended in these procedures.
AB - The efficacy of high-dose cytarabine (HDCA) plus cyclophosphamide/total-body irradiation (CY/TBI) has been proved in cord blood transplantation (CBT) for acute lymphoblastic leukaemia (ALL), but not in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT). In this cohort study, we compared the prognosis of CY/TBI (N = 1244) and HDCA/CY/TBI (N = 316) regimens in BMT/PBSCT for ALL. The addition of HDCA decreased post-transplant relapse, while significantly increasing non-relapse mortality (risk ratio, 1·33), and overall survival was not improved. The positive effects of HDCA reported in CBT cannot be extrapolated to BMT/PBSCT, and HDCA may not be recommended in these procedures.
KW - BMT/PBSCT
KW - acute lymphoblastic leukaemia
KW - allogeneic transplantation
KW - conditioning regimens
KW - high-dose cytarabine
UR - http://www.scopus.com/inward/record.url?scp=85018760119&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018760119&partnerID=8YFLogxK
U2 - 10.1111/bjh.14652
DO - 10.1111/bjh.14652
M3 - Article
C2 - 28439877
AN - SCOPUS:85018760119
SN - 0007-1048
VL - 178
SP - 106
EP - 111
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -